PL3302519T3 - Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu ostrej choroby przeszczep przeciwko gospodarzowi - Google Patents

Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu ostrej choroby przeszczep przeciwko gospodarzowi

Info

Publication number
PL3302519T3
PL3302519T3 PL15807907T PL15807907T PL3302519T3 PL 3302519 T3 PL3302519 T3 PL 3302519T3 PL 15807907 T PL15807907 T PL 15807907T PL 15807907 T PL15807907 T PL 15807907T PL 3302519 T3 PL3302519 T3 PL 3302519T3
Authority
PL
Poland
Prior art keywords
treatment
host disease
versus host
graft versus
complement inhibitor
Prior art date
Application number
PL15807907T
Other languages
English (en)
Inventor
Wynne H Weston-Davies
Original Assignee
Volution Immuno Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals Sa filed Critical Volution Immuno Pharmaceuticals Sa
Priority claimed from PCT/EP2015/079172 external-priority patent/WO2016198133A1/en
Publication of PL3302519T3 publication Critical patent/PL3302519T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL15807907T 2014-06-06 2015-12-09 Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu ostrej choroby przeszczep przeciwko gospodarzowi PL3302519T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1410116.6A GB201410116D0 (en) 2014-06-06 2014-06-06 Method of treatment
PCT/EP2015/062742 WO2015185760A1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism
PCT/EP2015/079172 WO2016198133A1 (en) 2015-06-08 2015-12-09 Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
EP15807907.9A EP3302519B1 (en) 2015-06-08 2015-12-09 Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease

Publications (1)

Publication Number Publication Date
PL3302519T3 true PL3302519T3 (pl) 2022-04-25

Family

ID=51266841

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15728491T PL3151851T3 (pl) 2014-06-06 2015-06-08 Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu chorób, w których pośredniczy dopełniacz, u pacjentów z polimorfizmem c5
PL15807907T PL3302519T3 (pl) 2014-06-06 2015-12-09 Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu ostrej choroby przeszczep przeciwko gospodarzowi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15728491T PL3151851T3 (pl) 2014-06-06 2015-06-08 Inhibitor dopełniacza ornithodoros moubata do zastosowania w leczeniu chorób, w których pośredniczy dopełniacz, u pacjentów z polimorfizmem c5

Country Status (16)

Country Link
US (3) US11052129B2 (pl)
EP (1) EP3151851B1 (pl)
JP (2) JP7045133B2 (pl)
KR (1) KR102439717B1 (pl)
CN (1) CN106659767B (pl)
AU (1) AU2015270396B2 (pl)
BR (1) BR112016028446A2 (pl)
CA (1) CA2951175A1 (pl)
DK (2) DK3151851T3 (pl)
ES (2) ES2906630T3 (pl)
GB (1) GB201410116D0 (pl)
IL (1) IL249237B (pl)
MX (1) MX382757B (pl)
PL (2) PL3151851T3 (pl)
RU (1) RU2700932C2 (pl)
WO (1) WO2015185760A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016198133A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) * 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
CN109328197A (zh) * 2016-06-07 2019-02-12 诺华股份有限公司 用于治疗具有补体c5多态性的患者的抗c5抗体
SE540754C2 (en) * 2016-11-30 2018-10-30 Ikea Supply Ag Molding of fiber blanks into three-dimensional fiber block
CN110831617A (zh) * 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054033A9 (en) * 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
GB0312619D0 (en) * 2003-06-02 2003-07-09 Evolutec Ltd Complement inhibitors
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
EP2061501B1 (en) * 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
CA2785612C (en) 2010-01-08 2019-09-10 Varleigh Immuno Pharmaceuticals (Vip) Ltd. Ev576 for use in the treatment of viral infections of the respiratory tract
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン

Also Published As

Publication number Publication date
JP2017518316A (ja) 2017-07-06
MX382757B (es) 2025-03-13
CN106659767B (zh) 2022-08-30
EP3151851A1 (en) 2017-04-12
EP3151851B1 (en) 2021-12-01
KR102439717B1 (ko) 2022-09-02
DK3151851T3 (da) 2022-02-28
CN106659767A (zh) 2017-05-10
DK3302519T3 (da) 2022-02-28
NZ727053A (en) 2023-10-27
BR112016028446A2 (pt) 2017-10-24
RU2016151179A (ru) 2018-07-16
IL249237A0 (en) 2017-02-28
ES2906632T3 (es) 2022-04-19
AU2015270396A1 (en) 2016-12-15
KR20170016893A (ko) 2017-02-14
US20170196936A1 (en) 2017-07-13
AU2015270396B2 (en) 2020-07-16
US20210283221A1 (en) 2021-09-16
RU2700932C2 (ru) 2019-09-24
CA2951175A1 (en) 2015-12-10
WO2015185760A1 (en) 2015-12-10
MX2016016139A (es) 2017-07-28
RU2016151179A3 (pl) 2019-01-22
GB201410116D0 (en) 2014-07-23
ES2906630T3 (es) 2022-04-19
JP2018516944A (ja) 2018-06-28
JP6767396B2 (ja) 2020-10-14
JP7045133B2 (ja) 2022-03-31
US11052129B2 (en) 2021-07-06
IL249237B (en) 2020-09-30
US20180193417A1 (en) 2018-07-12
PL3151851T3 (pl) 2022-04-04

Similar Documents

Publication Publication Date Title
IL264687B (en) cdk2/4/6 pyridopyrimidinone inhibitors
IL253945A0 (en) kdm1a inhibitors to treat the disease
GB201614522D0 (en) Use of cannabinoids in the treatment of multiple myeloma
PL3212208T3 (pl) Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
IL278247B (en) mct4 inhibitors to treat the disease
IL249237B (en) Ornithodorus Mobate complement inhibitor for use in the treatment of complement-induced diseases in patients with the c5 polymorphism
SG11201708075RA (en) Treatment of chronic graft versus host disease with syk inhibitors
IL251905A0 (en) Epilimod for use in the treatment of kidney cancer
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
PT3164394T (pt) Inibidores gls1 para o tratamento de doenças
ZA201701426B (en) Compounds for use in anthelminthic treatment
IL252904A0 (en) Methods and factors for treating diseases
HUE046209T2 (hu) Kompozíció porckoronggal összefüggõ fájdalom kezelésében történõ alkalmazásra
LT3200783T (lt) Eritromelalgijos gydymas
SI3548006T1 (sl) Sestava za uporabo pri zdravljenju črevesnih sprememb
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
GB201513543D0 (en) Compositions for use in the treatment of diabetes
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
GB201511772D0 (en) Improvements in the treatment of ash
EP3125903A4 (en) Method for use of homopiperazinium compounds in the treatment of cancer
EP3215154A4 (en) Salts and compositions useful for treating disease
GB201418526D0 (en) Kit and method for preventing or treating menopausal symptoms